drugset
drugset / Trial / NCT04032691

PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol

NCT04032691 ↗

Phase 0 Withdrawn Weill Medical College of Cornell University
NaSingle-groupOpen-labelBasic science

Summary

This investigator initiated, pilot study will assess the feasibility of characterizing the effects of an orally administered alpha-2 adrenergic (a2a) agonist, clonidine, on the clearance rates of Carbon-11 butanol from the ventricular cerebrospinal fluid (vCSF) with positron emission tomography (PET) in healthy volunteers.

Timeline

Start
2019-08-27
Primary completion
2021-05-24
Completion
2021-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Clonidine Other / unclassified 0.1 mg Oral

Indications

No indication recorded.